Phase I study of TAC-101, an oral synthetic retinoid, in Japanese patients with advanced hepatocellular carcinoma

Cancer Science

Volumn 103, Issue 8, 2012, Pages 1524-1530

  Okusaka, Takuji ^a   Ueno, Hideki ^a   Ikeda, Masafumi ^b   Takezako, Yoriko ^a   Morizane, Chigusa ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMSILAROTENE;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ARTHRALGIA; ARTICLE; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COUGHING; DISEASE CONTROL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; FATIGUE; FEMALE; HEADACHE; HUMAN; JAPANESE; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER CELL CARCINOMA; LOADING DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RACE DIFFERENCE; RASH; RECOMMENDED DRUG DOSE; RHINORRHEA; SIDE EFFECT; SPLENIC VEIN; SPLENIC VEIN THROMBOSIS; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VEIN THROMBOSIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BENZOATES; CARCINOMA, HEPATOCELLULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; TREATMENT OUTCOME; TRIMETHYLSILYL COMPOUNDS; YOUNG ADULT;

EID: 84864306685     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02334.x     Document Type: Article

References (9)

1. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005; 23: 2892-9.
2. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
3. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
4. Murakami K, Wierzba K, Sano M et al. TAC-101, a benzoic acid derivative, inhibits liver metastasis of human gastrointestinal cancer and prolongs the life-span. Clin Exp Metastasis 1998; 16: 323-31.
5. Murakami K, Matsuura T, Sano M et al. 4-[3, 5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals. Clin Exp Metastasis 1998; 16: 633-43.
6. Minagawa N, Nakayama Y, Inoue Y et al. 4-[3, 5-Bis(trimethylsilyl)benzamido] benzoic acid inhibits angiogenesis in colon cancer through reduced expression of vascular endothelial growth factor. Oncol Res 2004; 14: 407-14.
7. Rizvi NA, Marshall JL, Ness E et al. Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer. J Clin Oncol 2002; 20: 3522-32.
8. Higginbotham KB, Lozano R, Brown T et al. A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2008; 134: 1325-35.
9. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.